EUDA Health Signs Letter of Intent to Acquire iPSC Platform Developer GO POSB for Regenerative Medicine Expansion
核心洞察
EUDA Health Holdings Limited (搜索) has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd (搜索), a Singapore-based biotechnology company with a proprietary induced pluripotent stem cell platform.
GO POSB has developed technology that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells (搜索) capable of differentiating into nearly any cell type in the human body.
The collaboration plans to establish a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China, to serve hospitals, clinics, and research centers across the region.
EUDA Health Holdings Limited (搜索) (NASDAQ: EUDA), a Singapore-based non-invasive healthcare provider, announced that its wholly-owned subsidiary has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd (搜索), a biotechnology company that has developed a proprietary induced pluripotent stem cell (iPSC) platform. The acquisition represents a strategic expansion into regenerative medicine solutions for the Asian healthcare market.
Proprietary iPSC Technology Platform
GO POSB has developed a proprietary iPSC platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells (搜索). These iPSCs (搜索) can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. The technology provides pluripotency without the ethical concerns linked to embryonic stem cells, positioning iPSCs as one of the most promising frontiers in biotechnology.
Strategic Facility Development in China
Under the Letter of Intent, EUDA and GO POSB are exploring the establishment of a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China. The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals. EUDA will provide funding for the build-out while the two companies collaborate with Singapore's Agency for Science, Technology and Research (搜索) (A*STAR) to advance iPSC research, conduct clinical trials, and accelerate regulatory pathways for therapeutic applications.
B2B Healthcare Ecosystem Integration
The collaboration will position EUDA to supply B2B iPSC solutions to the downstream healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond core therapeutic applications, the platform opens future opportunities for off-the-shelf iPSC-derived product lines tailored for Asia's wellness and aesthetics markets, such as iPSC-based hair rejuvenation and facial treatments. These initiatives are designed to directly complement EUDA's growing portfolio of stem cell treatments and supplements, reinforcing the company's integrated approach to longevity and regenerative health.
Addressing Regional Healthcare Needs
EUDA aims to address the evolving healthcare needs of over 1.8 billion people across the Asia region, which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. The company is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care through innovative, accessible, and science-backed health solutions.